NCT04172506View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

January 30, 2022

Conditions
Solid TumorLung CancerHCC
Interventions
DRUG

AK105

Anti-PD-1 antibody

Trial Locations (1)

310003

The First Affiliated Hospital of Zhejiang University, Hangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY